Seo Young-Gyun
Department of Family Medicine, Hallym University Sacred Heart Hospital, Anyang, Korea.
J Obes Metab Syndr. 2021 Mar 30;30(1):12-19. doi: 10.7570/jomes20059.
Liraglutide is a glucagon-like peptide-1 receptor agonist used as a treatment for type 2 diabetes mellitus, which has been expanded for use at a higher dose in weight control. Therefore, it is necessary to consider adverse reactions of the drug at high doses as well as at lower doses after the indication has been expanded. Body mass index criteria for patients prescribed the drug in the real world tend to be applied less rigorously, which may increase the number of adverse reactions due to over-prescription. Liraglutide treatment was found effective and safe in some studies, while others have warned about its risks. Therefore, this review summarizes the current data available on side effects associated with liraglutide.
利拉鲁肽是一种胰高血糖素样肽-1受体激动剂，用于治疗2型糖尿病，已被批准以更高剂量用于体重控制。因此，在适应症扩大后，有必要考虑该药物高剂量和低剂量时的不良反应。在现实世界中，开具该药物的患者的体重指数标准往往应用不够严格，这可能会因处方过量而增加不良反应的数量。一些研究发现利拉鲁肽治疗有效且安全，而其他研究则警告了其风险。因此，本综述总结了目前关于利拉鲁肽相关副作用的现有数据。
